Ryan Selhorn is recorded as CFO at Aytu Biopharma, Inc (AYTU). The newest filing on record that lists Ryan Selhorn as CFO at Aytu Biopharma, Inc (AYTU) is dated October 22, 2026. Aytu Biopharma, Inc reported in an 8-K filed November 13, 2024 that Ryan Selhorn was appointed Chief Financial Officer. Aytu Biopharma, Inc reported in an 8-K filed November 13, 2024 that Ryan Selhorn was appointed Chief Financial Officer, Corporate Secretary and Treasurer, effective November 11, 2024. The proxy statement of Aytu Biopharma, Inc reports total compensation of $566,212 for Ryan Selhorn in fiscal 2026, including a base salary of $432,462. Disclosed compensation is on record for 2 fiscal years. Ryan Selhorn has spoken on 8 earnings calls across 1 company, most recently for Aytu Biopharma, Inc on September 22, 2026. Aytu Biopharma, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Aytu Biopharma, Inc includes Joshua R. Disbrow (CEO and Board Member), John A. Donofrio, Jr. (Chairman), Gregory A. Gould (CFO) and 7 others.
“The promotion of Ryan Selhorn, current Executive Vice President of Finance and Business Optimization, to the role of Chief Financial Officer, replacing Mark Oki, who will depart the Company;”
Aytu Biopharma, Inc Form 8-K, filed November 13, 2024
· Read the filing
“On November 11, 2024, the board of directors of the Company (the "Board") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.”
Aytu Biopharma, Inc Form 8-K, filed November 13, 2024
· Read the filing
Ryan Selhorn on recent calls
“I'll primarily cover our fourth quarter results and then spend a few minutes on our outlook and how we expect fiscal 2027 to unfold. Let's start on the revenue line.”
“Net revenue for the third quarter of fiscal 2026 was $12.4 million compared to $18.5 million for the prior year period. That represents a decrease of $6 million or 33% year over year.”
“Net revenue for the quarter was $15.2 million compared to $16.2 million for the prior year. Breaking net revenue down, the ADHD portfolio net revenue was $13.2 million compared to $13.8 million in the prior year period.”
“Please note that our June full year and fourth quarter fiscal 2025 financial results are detailed in both our press release and fiscal 2025 Form 10-K that we filed today with the SEC.”
